How is VYJUVEK's Commercial Performance Shaping Krystal Biotech's Outlook

Related Articles

What are the Major Headwinds and Tailwinds Shaping the Biotech Sector in 2026

3 months ago

What's Driving Paycom's Recent Performance and Cautious Outlook

2 months ago

What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook

3 months ago

Is EverPass Media Revolutionizing Commercial Sports Distribution

1 months ago

Category

You may also like

Stock News•1 week ago

Verrica Pharmaceuticals Q1 Earnings Call Highlights

Verrica Pharmaceuticals reported increased Q1 revenue driven by record demand for its YCANTH treatment. The company also advanced late-stage development programs for common warts and basal cell carcin...

VRCA

Share

Stock News•1 week ago

Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech maintains a $1B cash position to fund R&D without dilution, while its VYJUVEK platform generates 95% gross margins. The company projects annual net income could reach $1.8B–$2.9B as in...

KRYS

Share

Stock News•2 weeks ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) released its Q1 2026 earnings results via transcript. The report provides updated financial performance metrics and operational guidance for the current fiscal year, of...

BCRX

Share

Stock News•3 weeks ago

Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?

Regeneron Pharmaceuticals enters Q1 earnings with expectations that robust Dupixent profits and Eylea HD uptake will offset declining legacy Eylea sales. Investors are monitoring whether these growth ...

REGN

Share